Iwasa Y.-I. · Kitoh R. · Hiramatsu K. · Sugiyama K. · Watanabe K. · Yasukawa R. · Shinagawa J. · Miyajima H. · Yokota Y. · Kobayashi M. · Kitano T. · Mori K. · Takumi Y.

Author affiliations

Department of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, Matsumoto, Japan

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: June 14, 2022
Accepted: September 24, 2022
Published online: November 24, 2022

Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 3

ISSN: 0301-1569 (Print)
eISSN: 1423-0275 (Online)

For additional information: https://www.karger.com/ORL

Abstract

Introduction: Sarcopenia, characterized by low skeletal muscle mass, and the outcome of cancer therapy are closely related based on recent research. This study aimed to evaluate the correlation between skeletal muscle mass and prognosis in head and neck cancer (HNC) patients. Methods: In this study, 51 male patients with HNC treated nonsurgically between January 2016 and April 2018 at Shinshu University Hospital were evaluated. Skeletal muscle mass was assessed using bioelectrical impedance analysis, and the skeletal mass index (SMI) was calculated to classify the patients. Results: The low-SMI group had a significantly worse overall survival (OS) than the normal-SMI group (3-year OS: 72.0% vs. 93.0%, p = 0.014), and there was a trend toward worse progression-free survival (PFS) in the low-SMI group (3-year PFS: 49.6% vs. 79.3%, p = 0.064). Multivariate analysis also showed that low SMI (p = 0.04) and severe N stage (p = 0.009) were significantly associated with poorer OS. Conclusion: The pretreatment assessment of SMI using bioelectrical impedance analysis is useful for identifying patients with poor prognoses. To improve the treatment outcome in HNC, we need to think of the intervention, such as cancer rehabilitation and nutritional support, during or before treatment, especially for patients with low SMI.

© 2022 S. Karger AG, Basel

References Shimizu R, Honda M, Teraoka S, Yumioka T, Yamaguchi N, Kawamoto B, et al. Sarcopenia is associated with survival in patients with urothelial carcinoma treated with systemic chemotherapy. Int J Clin Oncol. 2021;27(1):175–83. Huang DD, Chen XX, Chen XY, Wang SL, Shen X, Chen XL, et al. Sarcopenia predicts 1-year mortality in elderly patients undergoing curative gastrectomy for gastric cancer: a prospective study. J Cancer Res Clin Oncol. 2016;142(11):2347–56. Rosenberg IH. Summary comments. Am J Clin Nutr. 1989;50(5):1231–3. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39(4):412–23. Shodo R, Yamazaki K, Ueki Y, Takahashi T, Horii A. Sarcopenia predicts a poor treatment outcome in patients with head and neck squamous cell carcinoma receiving concurrent chemoradiotherapy. Eur Arch Otorhinolaryngol. 2021;278(6):2001–9. Ganju RG, Morse R, Hoover A, TenNapel M, Lominska CE. The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiation. Radiother Oncol. 2019;137:117–24. Yamahara K, Mizukoshi A, Lee K, Ikegami S. Sarcopenia with inflammation as a predictor of survival in patients with head and neck cancer. Auris Nasus Larynx. 2021;48(5):1013–22. Xu LB, Zhang HH, Shi MM, Huang ZX, Zhang WT, Chen XD, et al. Metabolic syndrome-related sarcopenia is associated with worse prognosis in patients with gastric cancer: a prospective study. Eur J Surg Oncol. 2020;46(12):2262–9. Grossberg AJ, Rock CD, Edwards J, Mohamed ASR, Ruzensky D, Currie A, et al. Bioelectrical impedance analysis as a quantitative measure of sarcopenia in head and neck cancer patients treated with radiotherapy. Radiother Oncol. 2021;159:21–7. Ferrão B, Neves PM, Santos T, Capelas ML, Mäkitie A, Ravasco P. Body composition changes in patients with head and neck cancer under active treatment: a scoping review. Support Care Cancer. 2020;28(10):4613–25. Tanimoto Y, Watanabe M, Sun W, Tanimoto K, Shishikura K, Sugiura Y, et al. Association of sarcopenia with functional decline in community-dwelling elderly subjects in Japan. Geriatr Gerontol Int. 2013;13(4):958–63. Yoshimura N, Muraki S, Oka H, Iidaka T, Kodama R, Kawaguchi H, et al. Is osteoporosis a predictor for future sarcopenia or vice versa? Four-year observations between the second and third ROAD study surveys. Osteoporos Int. 2017;28(1):189–99. Yoshida D, Suzuki T, Shimada H, Park H, Makizako H, Doi T, et al. Using two different algorithms to determine the prevalence of sarcopenia. Geriatr Gerontol Int. 2014;14(Suppl 1):46–51. Powrózek T, Dziwota J, Małecka-Massalska T. Nutritional deficiencies in radiotherapy-treated head and neck cancer patients. J Clin Med. 2021;10(4):574–18. Looijaard SMLM, Te Lintel Hekkert ML, Wüst RCI, Otten RHJ, Meskers CGM, Maier AB. Pathophysiological mechanisms explaining poor clinical outcome of older cancer patients with low skeletal muscle mass. Acta Physiol. 2021;231(1):e13516. Wendrich AW, Swartz JE, Bril SI, Wegner I, de Graeff A, Smid EJ, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. Oral Oncol. 2017;71:26–33. Samuel SR, Maiya AG, Fernandes DJ, Guddattu V, Saxena PP, Kurian JR, et al. Effectiveness of exercise-based rehabilitation on functional capacity and quality of life in head and neck cancer patients receiving chemo-radiotherapy. Support Care Cancer. 2019;27(10):3913–20. Lonbro S, Dalgas U, Primdahl H, Overgaard J, Overgaard K. Feasibility and efficacy of progressive resistance training and dietary supplements in radiotherapy treated head and neck cancer patients-the DAHANCA 25A study. Acta Oncol. 2013;52(2):310–8. Hashida R, Kawaguchi T, Koya S, Hirota K, Goshima N, Yoshiyama T, et al. Impact of cancer rehabilitation on the prognosis of patients with hepatocellular carcinoma. Oncol Lett. 2020;19(3):2355–67. Prado CM, Orsso CE, Pereira SL, Atherton PJ, Deutz NEP. Effects of β-hydroxy β-methylbutyrate (HMB) supplementation on muscle mass, function, and other outcomes in patients with cancer: a systematic review. J Cachexia Sarcopenia Muscle. 2022;13(3):1623–41. Article / Publication Details

First-Page Preview

Received: June 14, 2022
Accepted: September 24, 2022
Published online: November 24, 2022

Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 3

ISSN: 0301-1569 (Print)
eISSN: 1423-0275 (Online)

For additional information: https://www.karger.com/ORL

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.